



Docket No.: A7542.0000/P001-H  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Ginette Serrero

Application No.: 10/607,974

Confirmation No.:

Filed: June 30, 2003

Art Unit: 1635

For: 88KDA TUMORIGENIC GROWTH  
FACTOR AND ANTAGONISTS

Examiner: T. Gibbs

**INFORMATION REGARDING RELATED APPLICATIONS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby brings to the Examiner's attention each of the pending applications filed by Applicant:

~~09/813,156~~  
~~10/218,509~~  
~~09/456,886~~  
~~09/880,842~~  
~~09/824,647~~  
~~10/298,540~~  
~~10/281,160~~  
~~10/321,587~~

Dated: October 8, 2003

Respectfully submitted,

By   
James W. Brady, Jr.

Registration No.: 32,115  
DICKSTEIN SHAPIRO MORIN &  
OSHINSKY LLP  
2101 L Street NW  
Washington, DC 20037-1526  
(202) 785-9700  
Attorney for Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/607,974
				Filing Date	June 30, 2003
				First Named Inventor	Ginette Serrero
				Art Unit	1635
				Examiner Name	T. Gibbs
Sheet	1	of	5	Attorney Docket Number	A7542.0000/P001-H

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	*AA	5,416,192	05/16/1995	Shoyab et al.	
	*AB	6,309,826	10/30/2001	Serrero	
	*AC	6,511,986	01/28/2003	Zhang et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	*BA	WO 91 15510 A	10/17/1991	Squibb Bristol Myers Co.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					T <sup>2</sup>
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	*CA	<u>Effect of Testosterone on the Growth Properties and on Epidermal Growth Factor Receptor Expression in the Teratoma-derived Tumorigenic Cell Line 1246-3A</u> , Serrero, G. et al., Cancer Research 52, 1992, pps. 4242-4247.			
	*CB	<u>Molecular Biology of the Cell</u> , Alberts, B., et al., Garland Publishing, Inc., 1983.			
	*CC	<u>Growth Factors in Development, Transformation, and Tumorigenesis</u> , Cross, M. et al., Cell, Vol. 64, 1991, pps. 271-280.			
	*CD	<u>Autocrine Secretion and Malignant Transformation of Cells</u> , Sporn, M.B. et al., The New England Journal of Medicine, Vol. 303, 1980, pps. 878-880.			
	*CE	<u>Purification of an Autocrine Growth Factor Homologous with Mouse Epithelin Precursor from a Highly Tumorigenic Cell Line</u> , Zhou, J. et al., The Journal of Biological Chemistry, Vol. 268, No. 15, 1993, pps. 10863-10869.			
	*CF	<u>The Epithelin Precursor Encodes Two Proteins with Opposing Activities on Epithelial Cell Growth</u> , Plowman, G. et al., The Journal of Biological Chemistry, Vol. 267, No. 18, 1992, pps. 13073-13078.			
	*CG	<u>Granulins, a Novel Class of Peptide from Leukocytes</u> , Bateman, A. et al., Biochemical and Biophysical Research Communications, Vol. 173, No. 3, 1990, pps. 1161-1168.			
	*CH	<u>A Synthetic Fragment of Rat Transforming Growth Factor with Receptor Binding and Antigenic Properties</u> , Nestor, J. et al., Biochemical and Biophysical Research Communications, Vol. 129, No. 1, 1985, pps. 226-232.			
	*CI	<u>In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of</u>			

*John C. [signature]*

1/27/06

Substitute for form 1449A/B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/607,974
			Filing Date	June 30, 2003
			First Named Inventor	Ginette Serrero
			Art Unit	1635
			Examiner Name	T. Gibbs
			Attorney Docket Number	A7542.0000/P001-H
Sheet	2	of	5	

		Human Pituitary Growth Hormone, Adelman, J. et al., DNA, Vol. 2, No. 3, 1983, pps. 183-193.	
	*CJ	An <i>In Vitro</i> Model to Study Adipose Differentiation in Serum-Free Medium, Serrero, G. et al., Analytical Biochemistry 120, 1982, pps. 351-359.	
	*CK	Study of a Teratoma-Derived Adipogenic Cell Line 1246 and Isolation of an Insulin-Independent Variant in Serum-Free Medium, Serrero-Dave, G., Cancer Center, University of California, pps. 366-376.	
	*CL	Tumorigenicity Associated with Loss of Differentiation and of Response to Insulin in the Adipogenic Cell Line 1246, Serrero, G., In Vitro Cellular & Developmental Biology, Vol. 21, No. 9, 1985, pps. 537-540.	
	*CM	Decreased Transforming Growth Factor- $\beta$ Response and Binding in Insulin-independent Teratoma-Derived Cell Lines with Increased Tumorigenic Properties, Serrero, G. et al., Journal of Cellular Physiology, 149, 1991, pps 503-511.	
	*CN	Growth Inhibition of Human Breast Cancer Cells <i>in Vitro</i> with an Antibody against the Type I Somatomedin Receptor, Arteaga, C. et al., Cancer Research 49, 1989, pps.6237-6241.	
	*CO	The Biological Effects of a High Molecular Weight Form of IGF II in a Pluripotential Human Teratocarcinoma Cell Line, Schofield, P. et al., Anticancer Research 14, 1994, pps. 533-538.	
	*CP	Gene therapy of murine teratocarcinoma: Separate functions for insulin-like growth factors I and II in immunogenicity and differentiation, Trojan, J. et al., Proc. Natl. Acad. Sci. USA, Vol. 91, 1994, pps. 6088-6092.	
	*CQ	Effect of Testosterone on the Growth Properties and on Epidermal Growth Factor Receptor Expression in the Teratoma-derived Tumorigenic Cell Line 1246-3A, Serrero, G. et al., Cancer Research 52, 1992, pps. 4242-4247.	
	*CR	Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNA, Trojan, J. et al., Science, Vol. 259, 1993, pps. 94-96.	
	*CS	Continuous cultures of fused cells secreting antibody of predefined specificity, Kohler, G. et al., Nature, Vol. 256, 1975, pps. 495-497.	
	*CT	Production of Monoclonal Antibodies: Strategy and Tactics, de St. Groth, S.F. et al., Journal of Immunology Methods, 35, 1980, pps. 1-21.	
	*CU	Hybridoma Techniques, Schreier, M. et al., Cold Spring Harbor Laboratory, 1980.	
	*CV	Generation of antibody activity from immunoglobulin polypeptide chains produced in <i>Escherichia coli</i> , Cabilly, S. et al., Proc. Natl. Acad. Sci. USA, Vol. 81, 1984, pps. 3273-3277.	
	*CW	Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, Morrison, S. et al., Proc. Natl. Acad. Sci. USA, Vol. 81, 1984, pps. 6851-6855.	
	*CX	Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells, Liu, A. et al., Proc. Natl. Acad. Sci. USA, Vol. 84, 1987, pps. 3439-3443.	
	*CY	<i>Escherichia coli</i> Secretion of an Active Chimeric Antibody Fragment, Better, M. et al., Science, Vol. 240, 1988, pps. 1041-1043.	
	*CZ	Reshaping human antibodies for therapy, Riechmann, L. et al., Nature, Vol. 332, 1988, pps. 323-327.	

*Anna C. JOL*

*1/27/06*

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/607,974
				Filing Date	June 30, 2003
				First Named Inventor	Ginette Serrero
				Art Unit	1635
				Examiner Name	T. Gibbs
Sheet	3	of	5	Attorney Docket Number	A7542.0000/P001-H

<input checked="" type="checkbox"/>	*CAA	<u>Antibody Humanization Using Monovalent Phage Display</u> , Baca, M. et al., J. Biol. Chem., Vol. 272, No. 16, 1997, pps. 10678-10684.	
<input type="checkbox"/>	*CBB	<u>A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab</u> , Rosok, M.J. et al., J. Biol. Chem., Vol. 271, No. 37, 1996, pps. 22611-22618.	
<input type="checkbox"/>	*CCC	<u>Improved Radioimaging and Tumor Localization with Monoclonal F(ab')</u> , Wahl, R.L. et al., The Journal of Nuclear Medicine, Vol. 24, No. 4, 1983, pps. 316-325.	
<input type="checkbox"/>	*CDD	<u>Clinical Use of a Monoclonal Antibody to Bombesin-like Peptide in Patients with Lung Cancer</u> , Mulshine, J.L., Annals New York Academy of Sciences, pps. 360-372.	
<input type="checkbox"/>	*CEE	<u>Antisense RNA inhibits splicing of pre-mRNA <i>in vitro</i></u> , Munroe, S.H., The EMBO Journal, Vol. 7, No. 8, 1988, pps. 2523-2532.	
<input type="checkbox"/>	*CFF	<u>Specific Synthesis of DNA <i>in Vitro</i> via a Polymerase-Catalyzed Chain Reaction</u> , Mulis, K.B. et al., Methods in Enzymology, Vol. 155, 1987, pps. 335-350.	
<input type="checkbox"/>	*CGG	<u>Antisense approaches to cancer gene therapy</u> , Mercola, D. et al., Cancer Gene Therapy, Vol. 2, No. 1, 1995, pps 47-59.	
<input type="checkbox"/>	*CHH	<u>Gene inhibition using antisense oligodeoxynucleotides</u> , Wagner, R. W., Nature, Vol. 372, 1994, pps. 333-335.	
<input type="checkbox"/>	*CII	<u>Molecular Cloning: A Laboratory Manual</u> , Maniatis, T. et al., Cold Spring Harbor Laboratory, 1982.	
<input type="checkbox"/>	*CJJ	<u>Design and Application of Antisense Oligonucleotides in Cell Culture, <i>in Vivo</i>, and as Therapeutic Agents</u> , Brysch, W. et al., Cellular and Molecular Neurobiology, Vol. 14, No. 5, 1994, pps. 557-568.	
<input type="checkbox"/>	*CKK	<u>Rational Design of Sequence-specific Oncogene Inhibitors Based on Antisense and Antigene Oligonucleotides</u> , Helene, C., Eur. J. Cancer, Vol. 27, No. 11, 1991, pps. 1466-1471.	
<input type="checkbox"/>	*CLL	<u>Optimization of Antisense Oligodeoxynucleotide Structure for Targeting <i>ber-abl</i>* mRNA</u> , Giles, R.V. et al., Blood, Vol. 86, No. 2, 1995, pps. 744-754.	
<input type="checkbox"/>	*CMM	<u>Extending the chemistry that supports genetic information transfer <i>in vivo</i>: Phosphorothioate DNA, phosphorothioate RNA, 2'-O-methyl RNA, and methylphosphonate DNA</u> , Thaler, D.S. et al., Proc. Natl. Acad. Sci. USA, Vol. 93, 1996, pps. 1352-1356	
<input type="checkbox"/>	*CNN	<u>Oligonucleotide N3'-P5' phosphoramidates as antisense agents</u> , Gryaznov, S. et al., Nucleic Acids Research, Vol. 24, No. 8, 1996, pps. 1508-1514.	
<input type="checkbox"/>	*COO	<u>Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells</u> , Lappalainen, K. et al., Biochimica et Biophysica Acta 1196, 1994, pps. 201-208.	
<input type="checkbox"/>	*CPP	<u>Block of AIDS-Kaposi's Sarcoma (KS) Cell Growth, Angiogenesis, and Lesion Formation in Nude Mice by Antisense Oligonucleotide Targeting Basic Fibroblast Growth Factor</u> , Ensoli, B. et al., The Journal of Clinical Investigation, Inc., Vol. 94, 1994, pps. 1736-1746.	
<input type="checkbox"/>	*CQQ	<u>Growth Inhibition of Malignant CD5+B (B-1) Cells by Antisense IL-10 Oligonucleotide</u> , Peng, B. et al., Leukemia Research, Vol. 19, No. 3, 1995, pps. 159-167.	
<input checked="" type="checkbox"/>	*CRR	<u>Review: Optimizing inducer and culture conditions for expression of foreign proteins under the control of the lac promoter</u> , Donovan, R.S. et al., Journal of Industrial Microbiology, 16, 1996, pps. 145-154.	

*Rua C. J. J.*

*1/27/06*

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/607,974
				Filing Date	June 30, 2003
				First Named Inventor	Ginette Serrero
				Art Unit	1635
				Examiner Name	T. Gibbs
				Attorney Docket Number	A7542.0000/P001-H
Sheet	4	of	5		

*CSS		Prokaryotic gene expression <i>in vitro</i> : Transcription-translation coupled systems, Cenatiempo, Y., Biochimie, 68, 1986, pps. 505-515.	
*CTT		Bacterial Regulation: Global Regulatory Networks, Gottesman, S., Ann. Rev. Genet., 18, 1984, pps. 415-441.	
*CUU		Regulation <i>In Vivo</i> of a Cloned Mammalian Gene: Cadmium Induces the Transcription of a Mouse Metallothionein Gene in SV40 Vectors, Hamer, D.H. et al., Journal of Molecular and Applied Genetics, Vol. 1, No. 4, 1982, pps. 273-288.	
*CVV		Functional Relationships between Transcriptional Control Signals of the Thymidine Kinase Gene of Herpes Simplex Virus, McKnight, S.L., Cell, Vol. 31, 1982, pps. 355-365.	
*CWW		Isolation of the yeast regulatory gene GAL4 and analysis of its dosage effects on the galactose/melibiose regulon, Johnston, S.A. et al., Proc. Natl. Acad. Sci. USA, 79, 1982, pps. 6971-6975.	
*CXX		<i>In vivo</i> sequence requirements of the SV40 early promoter region, Benoist, C. et al., Nature, Vol. 290, 1981, pps. 304-310.	
*CYY		Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme, Andersson, S. et al., The Journal of Biological Chemistry, Vol. 264, No. 14, 1989, pps. 8222-8229.	
*CZZ		Insulin and Insulin-like Growth Factor Signaling Are Defective in the MDA MB-468 Human Breast Cancer Cell Line, Sepp-Lorenzino, L. et al., Cell Growth & Differentiation, Vol. 5, 1994, pps. 1077-1083.	
*CAAA		Biochemical Analysis of the Epithelin Receptor, Culouscou, J.M. et al., The Journal of Biological Chemistry, Vol. 268, No. 14, 1993, pps. 10458-10462.	
*CBBB		Targeted Toxins as Anticancer Agents, Siegfal, C.B., Cancer, Vol. 74, No. 3, 1994, pps. 1006-1012.	
*CCCC		Zhang et al. Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 14202-14207 (November 1998).	
*CDDD		Crooke, S.T. in Antisense Research and Application (Stanley T. Crooke, Ed), Springer-Verlag, pp. 1-50, (July 1998).	
*CEEE		Branch, A.D., TIBS, Vol. 23, pp. 45-50 (February 1998).	
*CFFF		Gewirtz, A.M. et al. Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 3161-3163 (April 1996).	
*CGGG		Rojanasakul, Y. Advanced Drug Delivery Reviews, Vol. 18, pp. 115-131 (January 1996).	
*CHHH		Anderson, W.F. Nature, Vol. 392, Suppl. pp. 25-30 (April 1998).	
*CIII		Gura, T. Science, Vol. 278, pp. 1041-1042 (November 1997).	
*CJJJ		Resnicoff, M. et al. Cancer Res. Vol. 54, pp. 2218-2222 (April 1994).	
*CKKK		Zhang Haidi, "Overexpression of PC cell derived growth factor (PCDGF) contributes to the highly tumorigenic properties of producer cell line PC," DISS. ABSTR. INT., vol. 58, no. 11, 1998, page 5814-B XP001025915, abstract.	
*CLLL		Vijay Bandhari and Andrew Bateman, "Structure and Chromosomal Location of the human granulin gene," Biochemical and Biophysical Research Communications, vol. 188, no. 1, 1992, pages 57-63, XP001018991, abstract, figure 2.	
*CMMM		Bhandari et al., "The Complementary Deoxyribonucleic Acid Sequence, Tissue Distribution, and Cellular Localization of the Rat Granulin Precursor," Endocrinology, vol. 133, no. 6, 1993, pages 2682-2689, XP001021601.	

Sean C. [Signature]

1/21/06

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/607,974
				Filing Date	June 30, 2003
				First Named Inventor	Ginette Serrero
				Art Unit	1635
				Examiner Name	T. Gibbs
Sheet	5	of	5	Attorney Docket Number	A7542.0000/P001-H

<input checked="" type="checkbox"/>	*CENN	Haidi Zhang and Ginette Serrero, "Inhibition of tumorigenicity of the teratoma PC cell line by transfection with antisense cDNA for PC cell-derived growth factor (PCDGF, epithelin/granulin precursor)," PNAS, vol. 95, November 1998 (1998-11), pages 14202-14207, XP002177206.	
<input checked="" type="checkbox"/>	*COOO	European Search Report dated October 23, 2001	
<input checked="" type="checkbox"/>	*CPPP	Sigmund, C.D., "Viewpoint: Are studies in genetically altered mice out of control? Arteriosclerosis Thrombosis and Vascular Biology, 2000, Vol. 20:1425-1429.	
<input checked="" type="checkbox"/>	*CQQQ	Blackshear, P.E. Genetically engineered rodent models of mammary gland carcinogenesis: An overview. Toxicologic Pathology, 2001, Vol. 29:105-116.	
<input checked="" type="checkbox"/>	*CRRR	Runqing Lu, et al. - "Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468," PNAS, Vol. 97, No. 8, April 11, 2000, pgs. 3993-3998.	
<input checked="" type="checkbox"/>	*CSSS	Bijay Bhandari et al. - "Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cystein-rich granulin domains," Proc. Natl. Acad. Sci. USA, Vol. 89 March 1992, pgs. 1715-1719.	
<input checked="" type="checkbox"/>	*CTTT	Zhiheng, He et al. - "Progranulin Gene Expression Regulates Epithelial Cell Growth and Promotes Tumor Growth <i>in Vivo</i> ", Cancer Research 59, July 1, 1999, pgs. 3222-3229.	
<input checked="" type="checkbox"/>	*CUUU	International Search Report dated May 13, 2003.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

*Dir C. [Signature]* 1/27/06